Måndag 16 November | 22:46:52 Europe / Stockholm
Est. tid*
2027-02-25 08:45 Bokslutskommuniké 2026
2026-11-12 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-05-27 - X-dag ordinarie utdelning ALZ 0.00 SEK
2026-05-26 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-03-25 - Bokslutskommuniké 2025
2025-11-13 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning ALZ 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-03-07 - Extra Bolagsstämma 2025
2025-02-27 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning ALZ 0.00 SEK
2024-05-29 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-02-28 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-30 - Årsstämma
2023-05-25 - X-dag ordinarie utdelning ALZ 0.00 SEK
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2022-05-19 - Kvartalsrapport 2022-Q1
2022-05-18 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2021-05-19 - Kvartalsrapport 2021-Q1
2021-05-18 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2020-05-15 - Kvartalsrapport 2020-Q1
2020-05-14 - Årsstämma
2020-02-27 - Extra Bolagsstämma 2020
2020-02-26 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2019-05-17 - Kvartalsrapport 2019-Q1
2019-05-16 - Årsstämma
2019-02-26 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2018-05-18 - Kvartalsrapport 2018-Q1
2018-05-17 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2017-05-17 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-28 - Kvartalsrapport 2016-Q3
2016-08-29 - Kvartalsrapport 2016-Q2
2016-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2016-05-18 - Årsstämma
2016-05-18 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Alzinova är ett bioteknikbolag. Bolaget är specialiserat inom terapeutiskt behandling av Alzheimers och bedriver forskning och utveckling av peptider som vidareutvecklas som vaccin. Utöver det utvecklar bolaget även diverse forskningsverktyg inom arbetsområdet. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades år 2011 och har sitt huvudkontor i Mölndal.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Alzinova presents study design for Phase 2a ADVANCE trial with ALZ-101 at CTAD in Boston

2026-11-16 21:15:00

Alzinova AB (“Alzinova” or the “Company”) today announces that it is presenting the study design for the planned Phase 2a ADVANCE trial (ALZ-C-002) with its Alzheimer’s vaccine ALZ-101 at the international Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place on November 16–19, 2026, in Boston, USA. The poster is being presented by Stefan Pierrou, Vice President R&D Projects at Alzinova, together with co-authors including Anders Sandberg, Chief Scientific Officer, and Professor Marwan Sabbagh of Barrow Neurological Institute.

ALZ-101 is an active immunotherapy comprising an oligomerised, conformationally constrained Aβ42 derivative (Aβ42CC) formulated with an aluminium hydroxide adjuvant. It is designed to induce a polyclonal antibody response that specifically targets a subset of soluble amyloid-β (Aβ) oligomers — believed to play a central role in synaptic dysfunction and neurodegeneration in Alzheimer's disease — while limiting recognition of monomeric and fibrillar Aβ.

In the completed Phase 1 study (ALZ-C-001), ALZ-101 showed a favourable safety and tolerability profile and induced antigen-specific immune responses, with approximately 90% of participants classified as responders (Lovró et al., Alzheimer's Research & Therapy, 2026).

About the ADVANCE study
ADVANCE is a randomised, double-blind, placebo-controlled Phase 2a study that will evaluate the clinical efficacy, safety, tolerability, immunogenicity and biomarker effects of ALZ-101 in approximately 120 participants aged 50–85 years with early Alzheimer's disease, defined as mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease according to NIA-AA criteria. The study is being conducted in the United States, the European Union and the United Kingdom, with seven US clinical trial sites already selected.

The primary endpoint is the effect of ALZ-101 versus placebo on clinical progression, measured as change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) through Week 52 with a sample size that will provide 80% power. Participants will be randomised 2:1 to receive eight intramuscular injections of ALZ-101 (250 µg per dose) or placebo at Weeks 0, 4, 8, 16, 32, 48, 64 and 80, with follow-up through Week 92. Secondary endpoints include ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL for MCI, CSF neurofilament light chain, and ALZ-101-specific IgG antibody titres, as well as safety and tolerability. The study also includes exploratory biomarker endpoints, including plasma and CSF Aβ species and phosphorylated tau-217.

Enrolment of the first participant is planned for late December 2026. An interim analysis is planned for the third quarter of 2028, once approximately 50% of participants have completed the Week 52 assessment. The analysis will include a futility assessment and additional pre-specified evaluations, which will be described in a forthcoming company communication. Results from the study are anticipated in late 2029.

Comment from Tord Labuda:
"With ADVANCE, we are taking the next important step in the clinical development of ALZ-101. Following the positive safety and immunological results from Phase 1, we will now investigate whether our oligomer-specific treatment strategy significantly can influence disease progression in patients with early Alzheimer’s disease. Presenting the study design at CTAD provides an opportunity to showcase our clinical programme to the international research community. With patient enrolment planned around the turn of the year, we are approaching a significant milestone for the company."

About ALZ-101
ALZ-101 is Alzinova’s lead candidate, a therapeutic vaccine against Alzheimer’s disease. Alzinova’s patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers believed to be central to the onset and development of the disease with great accuracy. ALZ-101 has received Fast Track designation from the US FDA.

For further information, please contact:
Tord Labuda, CEO
E-mail: IR@alzinova.com

About Alzinova
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, with a focus on targeting toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million people affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, as well as the diagnostic project ALZ-401, which aims to develop a blood test to identify an increased risk of Alzheimer's disease before symptoms appear. The goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com